Dong-Wan Kim

Azd9291, an Irreversible Egfr Tki, Overcomes T790m-mediated Resistance to Egfr Inhibitors in Lung Cancer Oncology Innovative Medicines And

W. Pao, D. Cross, R. Rowlinson, 2022 .

PALETTE: A randomized, double-blind, phase III trial of pazopanib versus placebo in patients (pts) with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy-An EORTC STBSG Global Network Study (EORTC 62072).

J. Blay, A. Cesne, A. D. Dei Tos, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study)

S. Lim, Q. Ou, T. Reungwetwattana, 2023, Cancers.

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial

Mohamed Reda Keddar, P. Jewsbury, D. Morgensztern, 2024, Nature medicine.

Breast cancer, early stage

M. Espié, C. Mermel, R. Gelber, 2012 .